ZBB Considered Useless By NCI Staff (Privately)’ New Approach Groups Program Into Four Categories
In Brief: Upton Okays Laetrile Clinical Trials, To Seek Protocols From Clinicians For IND Request
Regulatory Agencies Get Data For Action Against One Of World’s Most Widely Used Carcinogens
Change In Method Of Counting Cancer Incidence Results In More Attributed To Work Hazards
IG Report Clears Shubik Of Conflict Of Interest Change
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Anthony Letai pledges to ensure stability for extramural and intramural cancer science









